Cel-Sci Corporation
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia. Show More...
-
Website http://cel-sci.com
-
Sector Health Care
-
Industry Biotechnology: Biological Products (No Diagnostic Substances)
-
Last Quote 2.10 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-09 2011-09 2012-09 2013-09 2014-09 2015-09 2016-09 2017-09 2018-09 2019-09 TTM Earnings Per Share USD -15.0 -37.25 -19.5 -16.5 -12.21 -10.51 -2.37 -1.91 -1.87 -0.71 -0.94 Dividends USD Payout Ratio % * Shares Mil 1.0 1.0 1.0 1.0 2.0 3.0 5.0 8.0 17.0 31.0 35.0 Book Value Per Share * USD 33.99 10.57 8.25 6.28 4.59 0.87 -0.61 0.010 -0.04 0.03 0.32 Free Cash Flow Per Share * USD -14.76 -27.45 -14.77 -11.53 -10.36 -8.13 -4.81 -2.53 -0.94 -0.59 Return on Assets % 21.35 -94.92 -101.73 -68.61 -189.46 -199.98 -84.79 -83.58 -121.31 -77.38 -105.73 Financial Leverage (Average) 1.36 2.05 2.29 1.62 1.84 32299.59 5.38 2.84 Return on Equity % 48.79 -145.02 -219.12 -134.48 -332.3 -862.18 -477.69 Return on Invested Capital % 45.34 -123.98 -217.3 -114.76 -293.25 -912.83 -138.24 -151.13 Interest Coverage -114.34 -55.69 -58.03 -52.81 -166.1 -265.76 Current Ratio 8.83 1.25 3.89 0.71 3.69 1.29 1.47 0.39 1.24 3.25 3.0 Quick Ratio 8.06 0.65 2.14 0.03 2.73 0.85 0.83 0.24 1.13 2.82 2.73 Debt/Equity 14606.95 2.63 1.07